Molecular genetic testing of the FMR1 gene is commonly performed in clinical laboratories. Pathogenic variants in the FMR1 gene are associated with fragile X syndrome, fragile X–associated tremor ataxia syndrome (FXTAS), and fragile X–associated primary ovarian insufficiency (FXPOI). This document provides updated information regarding FMR1 pathogenic variants, including prevalence, genotype–phenotype correlations, and variant nomenclature. Methodological considerations are provided for Southern blot analysis and polymerase chain reaction (PCR) amplification of FMR1, including triplet repeat–primed and methylation-specific PCR.
The American College of Medical Genetics and Genomics (ACMG) Laboratory Quality Assurance Committee has the mission of maintaining high technical standards for the performance and interpretation of genetic tests. In part, this is accomplished by the publication of the document ACMG Technical Standards for Clinical Genetics Laboratories, which is now maintained online (http://www.acmg.net). This subcommittee also reviews the outcome of national proficiency testing in the genetics area and may choose to focus on specific diseases or methodologies in response to those results. Accordingly, the subcommittee selected fragile X syndrome to be the first topic in a series of supplemental sections, recognizing that it is one of the most frequently ordered genetic tests and that it has many alternative methods with different strengths and weaknesses. This document is the fourth update to the original standards and guidelines for fragile X testing that were published in 2001, with revisions in 2005 and 2013, respectively.
Clarifies the clinical features associated with different FMRI variants (Section 2.3)
Discusses important reporting considerations (Section 188.8.131.52)
Provides updates on technology (Section 4.1)
Subscribe to Journal
Get full journal access for 1 year
only $33.25 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
Maddalena, A. et al. Technical standards and guidelines for fragile X: the first of a series of disease-specific supplements to the Standards and Guidelines for Clinical Genetics Laboratories of the American College of Medical Genetics. Genet. Med. 3, 200–205 (2001).
Spector, E. & Kronquist, K. Technical standards and guidelines for fragile X testing: a revision to the disease-specific supplements to the Standards and Guidelines for Clinical Genetics Laboratories of the American College of Medical Genetics. 2005 (online publication) (retired).
Monaghan, K. G. et al. ACMG Standards and Guidelines for fragile X testing: a revision to the disease-specific supplements to the Standards and Guidelines for Clinical Genetics Laboratories of the American College of Medical Genetics and Genomics. Genet. Med. 15, 575–586 (2013).
Yates, B. et al. Genenames.org: the HGNC and VGNC resources in 2017. Nucleic Acids Res. 45, D619–D625 (2017).
Online Mendelian Inheritance in Man. https://omim.org (2020).
Tassone, F. et al. Clinical involvement and protein expression in individuals with the FMR1 premutation. Am. J. Med. Genet. 91, 144–152 (2000).
Farzin, F. et al. Autism spectrum disorders and attention-deficit/hyperactivity disorder in boys with the fragile X premutation. J. Dev. Behav. Pediatr. 27, S137–144 (2006).
Hundscheid, R. D. L., Smits, A. P. T., Thomas, C. M. G., Kiemeney, L. A. L. M. & Braat, D. D. M. Female carriers of fragile X premutations have no increased risk for additional diseases other than premature ovarian failure. Am. J. Med. Genet. A. 117A, 6–9 (2003).
Sherman, S. L. Premature ovarian failure in the fragile X syndrome. Am. J. Med. Genet. 97, 189–194 (2000).
Murray, A., Ennis, S. & Morton, N. No evidence for parent of origin influencing premature ovarian failure in fragile X premutation carriers. Am. J. Hum. Genet. 67, 253–254 (2000). author reply 256-258.
Murray, A. Premature ovarian failure and the FMR1 gene. Semin. Reprod. Med. 18, 59–66 (2000).
Marozzi, A. et al. Association between idiopathic premature ovarian failure and fragile X premutation. Hum. Reprod. 15, 197–202 (2000).
Wittenberger, M. D. et al. The FMR1 premutation and reproduction. Fertil. Steril. 87, 456–465 (2007).
Spath, M. A. et al. Predictors and risk model development for menopausal age in fragile X premutation carriers. Genet. Med. 13, 643–650 (2011).
Bennett, C. E., Conway, G. S., Macpherson, J. N., Jacobs, P. A. & Murray, A. Intermediate sized CGG repeats are not a common cause of idiopathic premature ovarian failure. Hum. Reprod. 25, 1335–1338 (2010).
Tassone, F. et al. Intranuclear inclusions in neural cells with premutation alleles in fragile X associated tremor/ataxia syndrome. J. Med. Genet. 41, e43 (2004).
Rogers, C., Partington, M. W. & Turner, G. M. Tremor, ataxia and dementia in older men may indicate a carrier of the fragile X syndrome. Clin. Genet. 64, 54–56 (2003).
Rodriguez-Revenga, L. et al. Penetrance of FMR1 premutation associated pathologies in fragile X syndrome families. Eur. J. Hum. Genet. 17, 1359–1362 (2009).
Jacquemont, S. et al. Penetrance of the fragile X–associated tremor/ataxia syndrome in a premutation carrier population. JAMA. 291, 460–469 (2004).
Jacquemont, S. et al. Fragile X premutation tremor/ataxia syndrome: molecular, clinical, and neuroimaging correlates. Am. J. Hum. Genet. 72, 869–878 (2003).
Hagerman, R. J. et al. Fragile-X-associated tremor/ataxia syndrome (FXTAS) in females with the FMR1 premutation. Am. J. Hum. Genet. 74, 1051–1056 (2004).
Hagerman, P. J., Greco, C. M. & Hagerman, R. J. A cerebellar tremor/ataxia syndrome among fragile X premutation carriers. Cytogenet. Genome Res. 100, 206–212 (2003).
Tassone, F. et al. CGG repeat length correlates with age of onset of motor signs of the fragile X–associated tremor/ataxia syndrome (FXTAS). Am. J. Med. Genet. B Neuropsychiatr. Genet. 144B, 566–569 (2007).
Leehey, M. A. et al. FMR1 CGG repeat length predicts motor dysfunction in premutation carriers. Neurology. 70, 1397–1402 (2008).
Berry-Kravis, E. et al. Fragile X–associated tremor/ataxia syndrome: clinical features, genetics, and testing guidelines. Mov. Disord. 22, 2018–2030 (2007). quiz 2140.
Hagerman, R. J. et al. Fragile X–associated neuropsychiatric disorders (FXAND). Front. Psychiatry. 9, 564 (2018).
Alvarez-Mora, M. I. et al. Paternal transmission of a FMR1 full mutation allele. Am. J. Med. Genet. A. 173, 2795–2797 (2017).
Fisch, G. S. et al. The fragile X premutation in carriers and its effect on mutation size in offspring. Am. J. Hum. Genet. 56, 1147–1155 (1995).
Sutcliffe, J. S. et al. DNA methylation represses FMR-1 transcription in fragile X syndrome. Hum. Mol. Genet. 1, 397–400 (1992).
Kenneson, A., Zhang, F., Hagedorn, C. H. & Warren, S. T. Reduced FMRP and increased FMR1 transcription is proportionally associated with CGG repeat number in intermediate-length and premutation carriers. Hum. Mol. Genet. 10, 1449–1454 (2001).
O’Donnell, W. T. & Warren, S. T. A decade of molecular studies of fragile X syndrome. Annu. Rev. Neurosci. 25, 315–338 (2002).
Irwin, S. A., Galvez, R. & Greenough, W. T. Dendritic spine structural anomalies in fragile-X mental retardation syndrome. Cereb. Cortex. 10, 1038–1044 (2000).
Hinton, V. J., Brown, W. T., Wisniewski, K. & Rudelli, R. D. Analysis of neocortex in three males with the fragile X syndrome. Am. J. Med. Genet. 41, 289–294 (1991).
Feng, Y. et al. Fragile X mental retardation protein: nucleocytoplasmic shuttling and association with somatodendritic ribosomes. J. Neurosci. 17, 1539–1547 (1997).
Li, Z. et al. The fragile X mental retardation protein inhibits translation via interacting with mRNA. Nucleic Acids Res. 29, 2276–2283 (2001).
Bardoni, B. & Mandel, J. L. Advances in understanding of fragile X pathogenesis and FMRP function, and in identification of X linked mental retardation genes. Curr. Opin. Genet. Dev. 12, 284–293 (2002).
Aschrafi, A., Cunningham, B. A., Edelman, G. M. & Vanderklish, P. W. The fragile X mental retardation protein and group I metabotropic glutamate receptors regulate levels of mRNA granules in brain. Proc. Natl. Acad. Sci. U. S. A. 102, 2180–2185 (2005).
Tassone, F. et al. Elevated levels of FMR1 mRNA in carrier males: a new mechanism of involvement in the fragile-X syndrome. Am. J. Hum. Genet. 66, 6–15 (2000).
Tassone, F., Hagerman, R. J., Chamberlain, W. D. & Hagerman, P. J. Transcription of the FMR1 gene in individuals with fragile X syndrome. Am. J. Med. Genet. 97, 195–203 (2000).
Beilina, A., Tassone, F., Schwartz, P. H., Sahota, P. & Hagerman, P. J. Redistribution of transcription start sites within the FMR1 promoter region with expansion of the downstream CGG-repeat element. Hum. Mol. Genet. 13, 543–549 (2004).
Galloway, J. N. & Nelson, D. L. Evidence for RNA-mediated toxicity in the fragile X–associated tremor/ataxia syndrome. Future Neurol. 4, 785 (2009).
Sellier, C. et al. Translation of expanded CGG repeats into FMRpolyG is pathogenic and may contribute to fragile X tremor ataxia syndrome. Neuron. 93, 331–347 (2017).
Hunter, J. et al. Epidemiology of fragile X syndrome: a systematic review and meta-analysis. Am. J. Med. Genet. A. 164A, 1648–1658 (2014).
Cronister, A., DiMaio, M., Mahoney, M. J., Donnenfeld, A. E. & Hallam, S. Fragile X syndrome carrier screening in the prenatal genetic counseling setting. Genet. Med. 7, 246–250 (2005).
Strom, C. M. et al. Molecular testing for fragile X syndrome: lessons learned from 119,232 tests performed in a clinical laboratory. Genet. Med. 9, 46–51 (2007).
Owens, K. M. et al. FMR1 premutation frequency in a large, ethnically diverse population referred for carrier testing. Am. J. Med. Genet. A. 176, 1304–1308 (2018).
Levesque, S. et al. Screening and instability of FMR1 alleles in a prospective sample of 24,449 mother-newborn pairs from the general population. Clin. Genet. 76, 511–523 (2009).
Rousseau, F., Rouillard, P., Morel, M. L., Khandjian, E. W. & Morgan, K. Prevalence of carriers of premutation-size alleles of the FMRI gene–and implications for the population genetics of the fragile X syndrome. Am. J. Hum. Genet. 57, 1006–1018 (1995).
Dombrowski, C. et al. Premutation and intermediate-size FMR1 alleles in 10,572 males from the general population: loss of an AGG interruption is a late event in the generation of fragile X syndrome alleles. Hum. Mol. Genet. 11, 371–378 (2002).
Berkenstadt, M., Ries-Levavi, L., Cuckle, H., Peleg, L. & Barkai, G. Preconceptional and prenatal screening for fragile X syndrome: experience with 40,000 tests. Prenat. Diagn. 27, 991–994 (2007).
Pesso, R. et al. Screening for fragile X syndrome in women of reproductive age. Prenat. Diagn. 20, 611–614 (2000).
Hagerman, P. J. The fragile X prevalence paradox. J. Med. Genet. 45, 498–499 (2008).
Toledano-Alhadef, H. et al. Fragile-X carrier screening and the prevalence of premutation and full-mutation carriers in Israel. Am. J. Hum. Genet. 69, 351–360 (2001).
Falik-Zaccai, T. C. et al. Predisposition to the fragile X syndrome in Jews of Tunisian descent is due to the absence of AGG interruptions on a rare Mediterranean haplotype. Am. J. Hum. Genet. 60, 103–112 (1997).
Tzeng, C. C. et al. Prevalence of the FMR1 mutation in Taiwan assessed by large-scale screening of newborn boys and analysis of DXS548-FRAXAC1 haplotype. Am. J. Med. Genet. A. 133A, 37–43 (2005).
Cellini, E. et al. Fragile X premutation with atypical symptoms at onset. Arch. Neurol. 63, 1135–1138 (2006).
Sullivan, S. D., Welt, C. & Sherman, S. FMR1 and the continuum of primary ovarian insufficiency. Semin. Reprod. Med. 29, 299–307 (2011).
De Caro, J. J., Dominguez, C. & Sherman, S. L. Reproductive health of adolescent girls who carry the FMR1 premutation: expected phenotype based on current knowledge of fragile X-associated primary ovarian insufficiency. Ann. N. Y. Acad. Sci. 1135, 99–111 (2008).
Folsom, T. D., Thuras, P. D. & Fatemi, S. H. Protein expression of targets of the FMRP regulon is altered in brains of subjects with schizophrenia and mood disorders. Schizophr. Res. 165, 201–211 (2015).
American College of Obstetricians and Gynecologists Committee on Genetics. ACOG Committee Opinion No. 469: carrier screening for fragile X syndrome. Obstet. Gynecol. 116, 1008–1010 (2010).
Committee on Genetics. Committee Opinion No. 691: carrier screening for genetic conditions. Obstet. Gynecol. 129, e41–e55 (2017).
Kronquist, K. E., Sherman, S. L. & Spector, E. B. Clinical significance of tri-nucleotide repeats in fragile X testing: a clarification of American College of Medical Genetics guidelines. Genet. Med. 10, 845–847 (2008).
Sherman, S., Pletcher, B. A. & Driscoll, D. A. Fragile X syndrome: diagnostic and carrier testing. Genet. Med. 7, 584–587 (2005).
Finucane, B. et al. Genetic counseling and testing for FMR1 gene mutations: practice guidelines of the National Society of Genetic Counselors. J. Genet. Couns. 21, 752–760 (2012).
Weinstein, V., Tanpaiboon, P., Chapman, K. A., Ah Mew, N. & Hofherr, S. Do the data really support ordering fragile X testing as a first-tier test without clinical features? Genet. Med. 19, 1317–1322 (2017).
Borch, L. A., Parboosingh, J., Thomas, M. A. & Veale, P. Re-evaluating the first-tier status of fragile X testing in neurodevelopmental disorders. Genet. Med. 22, 1036–1039 (2020).
de Vries, B. B. et al. Mental status of females with an FMR1 gene full mutation. Am. J. Hum. Genet. 58, 1025–1032 (1996).
Hagerman, R. J. et al. Girls with fragile X syndrome: physical and neurocognitive status and outcome. Pediatrics. 89, 395–400 (1992).
Willemsen, R., Bontekoe, C. J., Severijnen, L. A. & Oostra, B. A. Timing of the absence of FMR1 expression in full mutation chorionic villi. Hum. Genet. 110, 601–605 (2002).
Maddalena, A., Hicks, B. D., Spence, W. C., Levinson, G. & Howard-Peebles, P. N. Prenatal diagnosis in known fragile X carriers. Am. J. Med. Genet. 51, 490–496 (1994).
Oostra, B. A. & Willemsen, R. Diagnostic tests for fragile X syndrome. Expert. Rev. Mol. Diagn. 1, 226–232 (2001).
den Dunnen, J. T. et al. HGVS recommendations for the description of sequence variants: 2016 update. Hum. Mutat. 37, 564–569 (2016).
Weck, K. E., Zehnbauer, B., Datto, M. & Schrijver, I. Molecular genetic testing for fragile X syndrome: laboratory performance on the College of American Pathologists proficiency surveys (2001-2009). Genet. Med. 14, 306–312 (2012).
Nolin, S. L. et al. Expansions and contractions of the FMR1 CGG repeat in 5,508 transmissions of normal, intermediate, and premutation alleles. Am. J. Med. Genet. A. 179, 1148–1156 (2019).
Nolin, S. L. et al. Familial transmission of the FMR1 CGG repeat. Am. J. Hum. Genet. 59, 1252–1261 (1996).
Hagerman, P. J. & Hagerman, R. J. Fragile X–associated tremor/ataxia syndrome. Ann. N. Y. Acad. Sci. 1338, 58–70 (2015).
Hall, D., Tassone, F., Klepitskaya, O. & Leehey, M. Fragile X–associated tremor ataxia syndrome in FMR1 gray zone allele carriers. Mov. Disord. 27, 296–300 (2012).
Fernandez-Carvajal, I. et al. Expansion of an FMR1 grey-zone allele to a full mutation in two generations. J. Mol. Diagn. 11, 306–310 (2009).
Manor, E. et al. The role of AGG interruptions in the FMR1 gene stability: a survey in ethnic groups with low and high rate of consanguinity. Mol. Genet. Genomic Med. 7, e00946 (2019).
Hunter, J. E., Abramowitz, A., Rusin, M. & Sherman, S. L. Is there evidence for neuropsychological and neurobehavioral phenotypes among adults without FXTAS who carry the FMR1 premutation? A review of current literature. Genet. Med. 11, 79–89 (2009).
Kallinen, J., Heinonen, S., Mannermaa, A. & Ryynanen, M. Prenatal diagnosis of fragile X syndrome and the risk of expansion of a premutation. Clin. Genet. 58, 111–115 (2000).
Nolin, S. L. et al. Expansion of the fragile X CGG repeat in females with premutation or intermediate alleles. Am. J. Hum. Genet. 72, 454–464 (2003).
Godler, D. E. et al. Methylation of novel markers of fragile X alleles is inversely correlated with FMRP expression and FMR1 activation ratio. Hum. Mol. Genet. 19, 1618–1632 (2010).
Wakeling, E. N., Nahhas, F. A. & Feldman, G. L. Extra alleles in FMR1 triple-primed PCR: artifact, aneuploidy, or somatic mosaicism? J. Mol. Diagn. 16, 689–696 (2014).
Hagerman, R. J. et al. High functioning fragile X males: demonstration of an unmethylated fully expanded FMR-1 mutation associated with protein expression. Am. J. Med. Genet. 51, 298–308 (1994).
Rousseau, F., Robb, L. J., Rouillard, P. & Der Kaloustian, V. M. No mental retardation in a man with 40% abnormal methylation at the FMR-1 locus and transmission of sperm cell mutations as premutations. Hum. Mol. Genet. 3, 927–930 (1994).
Schmucker, B. & Seidel, J. Mosaicism for a full mutation and a normal size allele in two fragile X males. Am. J. Med. Genet. 84, 221–225 (1999).
Smeets, H. J. et al. Normal phenotype in two brothers with a full FMR1 mutation. Hum. Mol. Genet. 4, 2103–2108 (1995).
Hensel, C. H. et al. Abnormally methylated FMR1 in absence of a detectable full mutation in a U.S.A patient cohort referred for fragile X testing. Sci. Rep. 9, 15315 (2019).
Yrigollen, C. M. et al. AGG interruptions within the maternal FMR1 gene reduce the risk of offspring with fragile X syndrome. Genet. Med. 14, 729–736 (2012).
Nolin, S. L. et al. Fragile X full mutation expansions are inhibited by one or more AGG interruptions in premutation carriers. Genet. Med. 17, 358–364 (2015).
Yrigollen, C. M. et al. AGG interruptions and maternal age affect FMR1 CGG repeat allele stability during transmission. J. Neurodev. Disord. 6, 24 (2014).
Latham, G. J., Coppinger, J., Hadd, A. G. & Nolin, S. L. The role of AGG interruptions in fragile X repeat expansions: a twenty-year perspective. Front. Genet. 5, 244 (2014).
Ardui, S. et al. Detecting AGG interruptions in females with a FMR1 premutation by long-read single-molecule sequencing: a 1 year clinical experience. Front. Genet. 9, 150 (2018).
Amos Wilson, J. et al. Consensus characterization of 16 FMR1 reference materials: a consortium study. J. Mol. Diagn. 10, 2–12 (2008).
Nakahori, Y. et al. Molecular heterogeneity of the fragile X syndrome. Nucleic Acids Res. 19, 4355–4359 (1991).
Rousseau, F. et al. Direct diagnosis by DNA analysis of the fragile X syndrome of mental retardation. N. Engl. J. Med. 325, 1673–1681 (1991).
Verkerk, A. J. et al. Identification of a gene (FMR-1) containing a CGG repeat coincident with a breakpoint cluster region exhibiting length variation in fragile X syndrome. Cell. 65, 905–914 (1991).
Yu, S. et al. Fragile X genotype characterized by an unstable region of DNA. Science. 252, 1179–1181 (1991).
Brown, W. T. et al. Rapid fragile X carrier screening and prenatal diagnosis using a nonradioactive PCR test. JAMA. 270, 1569–1575 (1993).
Erster, S. H. et al. Polymerase chain reaction analysis of fragile X mutations. Hum. Genet. 90, 55–61 (1992).
Fu, Y. H. et al. Variation of the CGG repeat at the fragile X site results in genetic instability: resolution of the Sherman paradox. Cell. 67, 1047–1058 (1991).
Yu, S. et al. Fragile-X syndrome: unique genetics of the heritable unstable element. Am. J. Hum. Genet. 50, 968–980 (1992).
Das, S. et al. Methylation analysis of the fragile X syndrome by PCR. Genet. Test. 1, 151–155 (1997–1998).
Panagopoulos, I., Lassen, C., Kristoffersson, U. & Aman, P. A methylation PCR approach for detection of fragile X syndrome. Hum. Mutat. 14, 71–79 (1999).
de Graaff, E. et al. Hotspot for deletions in the CGG repeat region of FMR1 in fragile X patients. Hum. Mol. Genet. 4, 45–49 (1995).
Chen, L. et al. An information-rich CGG repeat primed PCR that detects the full range of fragile X expanded alleles and minimizes the need for southern blot analysis. J. Mol. Diagn. 12, 589–600 (2010).
Chen, L. et al. High-resolution methylation polymerase chain reaction for fragile X analysis: evidence for novel FMR1 methylation patterns undetected in southern blot analyses. Genet. Med. 13, 528–538 (2011).
Hantash, F. M. et al. Qualitative assessment of FMR1 (CGG)n triplet repeat status in normal, intermediate, premutation, full mutation, and mosaic carriers in both sexes: implications for fragile X syndrome carrier and newborn screening. Genet. Med. 12, 162–173 (2010).
Lyon, E. et al. A simple, high-throughput assay for fragile X expanded alleles using triple repeat primed PCR and capillary electrophoresis. J. Mol. Diagn. 12, 505–511 (2010).
Nahhas, F. A. et al. Evaluation of the human fragile X mental retardation 1 polymerase chain reaction reagents to amplify the FMR1 gene: testing in a clinical diagnostic laboratory. Genet. Test. Mol. Biomarkers. 16, 187–192 (2012).
Tassone, F., Pan, R., Amiri, K., Taylor, A. K. & Hagerman, P. J. A rapid polymerase chain reaction-based screening method for identification of all expanded alleles of the fragile X (FMR1) gene in newborn and high-risk populations. J. Mol. Diagn. 10, 43–49 (2008).
Zhou, Y. et al. Robust fragile X (CGG)n genotype classification using a methylation specific triple PCR assay. J. Med. Genet. 41, e45 (2004).
Nygren, A. O. H., Lens, S. I. & Carvalho, R. Methylation-specific multiplex ligation-dependent probe amplification enables a rapid and reliable distinction between male FMR1 premutation and full-mutation alleles. J. Mol. Diagn. 10, 496–501 (2008).
Elias, M. H. et al. A new method for FMR1 gene methylation screening by multiplex methylation-specific real-time polymerase chain reaction. Genet. Test. Mol. Biomarkers. 15, 387–393 (2011).
Schaefer, G. B. & Mendelsohn, N. J. Clinical genetics evaluation in identifying the etiology of autism spectrum disorders: 2013 guideline revisions. Genet. Med. 15, 399–407 (2013).
Shaffer, L. G. American College of Medical Genetics guideline on the cytogenetic evaluation of the individual with developmental delay or mental retardation. Genet. Med. 7, 650–654 (2005).
Heitz, D., Devys, D., Imbert, G., Kretz, C. & Mandel, J. L. Inheritance of the fragile X syndrome: size of the fragile X premutation is a major determinant of the transition to full mutation. J. Med. Genet. 29, 794–801 (1992).
Patsalis, P. C. et al. Genetic variation and intergenerational FMR1 CGG-repeat stability in 100 unrelated three-generation families from the normal population. Am. J. Med. Genet. 84, 217–220 (1999).
Rife, M. et al. Analysis of CGG variation through 642 meioses in fragile X families. Mol. Hum. Reprod. 10, 773–776 (2004).
Zeesman, S. et al. Paternal transmission of fragile X syndrome. Am. J. Med. Genet. A. 129A, 184–189 (2004).
Bahlo, M. et al. Recent advances in the detection of repeat expansions with short-read next-generation sequencing. F1000Res. 7, F1000 (2018).
Tankard, R. M. et al. Detecting expansions of tandem repeats in cohorts sequenced with short-read sequencing data. Am. J. Hum. Genet. 103, 858–873 (2018).
Dolzhenko, E. et al. Detection of long repeat expansions from PCR-free whole-genome sequence data. Genome Res. 27, 1895–1903 (2017).
Dashnow, H. et al. STRetch: detecting and discovering pathogenic short tandem repeat expansions. Genome Biol. 19, 121 (2018).
Mousavi, N., Shleizer-Burko, S., Yanicky, R. & Gymrek, M. Profiling the genome-wide landscape of tandem repeat expansions. Nucleic Acids Res. 47, e90 (2019).
Loomis, E. W. et al. Sequencing the unsequenceable: expanded CGG-repeat alleles of the fragile X gene. Genome Res. 23, 121–128 (2013).
Fragile X syndrome: diagnostic and carrier testing. Am. J. Med. Genet. 53, 380–381 (1994).
E.S., A.B., K.K., and H.V.R. direct or work in laboratories that offer clinical molecular genetic testing for fragile X syndrome. N.C.R. and E.L. declare no competing interests.
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
This technical standard is designed primarily as an educational resource for clinical laboratory geneticists to help them provide quality clinical laboratory genetic services. Adherence to this technical standard is voluntary and does not necessarily assure a successful medical outcome. This technical standard should not be considered inclusive of all proper procedures and tests or exclusive of other procedures and tests that are reasonably directed to obtaining the same results. In determining the propriety of any specific procedure or test, the clinical laboratory geneticist should apply his or her own professional judgment to the specific circumstances presented by the individual patient or specimen.
Clinical laboratory geneticists are encouraged to document in the patient’s record the rationale for the use of a particular procedure or test, whether or not it is in conformance with this technical standard. They also are advised to take notice of the date any particular technical standard was adopted, and to consider other relevant medical and scientific information that becomes available after that date. It also would be prudent to consider whether intellectual property interests may restrict the performance of certain tests and other procedures.
This document supersedes the Technical Standards and Guidelines for Fragile X Testing: The First of a Series of Disease-Specific Supplements to the Standards and Guidelines for Clinical Genetics Laboratories of the American College of Medical Genetics and Genomics (2001),1 the Technical Standards and Guidelines for Fragile X Testing: A Revision to the Disease-Specific Supplements to the Standards and Guidelines for Clinical Genetics Laboratories of the American College of Medical Genetics and Genomics (2005)2 and the ACMG Standards and Guidelines for Fragile X testing: a revision to the disease-specific supplements to the Standards and Guidelines for Clinical Genetics Laboratories of the American College of Medical Genetics and Genomics (2013).3 It is designed for genetic testing professionals who are already familiar with the disease and the methods of analysis.
The Board of Directors of the American College of Medical Genetics and Genomics approved this technical standard on 14 December 2020.
About this article
Cite this article
Spector, E., Behlmann, A., Kronquist, K. et al. Laboratory testing for fragile X, 2021 revision: a technical standard of the American College of Medical Genetics and Genomics (ACMG). Genet Med (2021). https://doi.org/10.1038/s41436-021-01115-y